Cindy Phan, MD
Obstetrics/Gynecology · Daly City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Phan’s office at (650) 301-5860 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A86593 · Current
Licensed to practise in California · since 2004 · expires 2027-07-31 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$7,561
Pharmacies billed $7,561 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
88 generic and fewer than 11 brand-name prescriptions · $7,561 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 19 | $1,228 | $42 |
Year by year
| 2024 | 99 | 50 | None | None | $7,561 |
| 2023 | 66 | 46 | None | None | $4,717 |
| 2022 | 59 | 41 | None | None | $3,788 |
| 2021 | 67 | 42 | 0% (0) | 18% | $6,207 |
| 2020 | 60 | 40 | None | None | $3,768 |
| 2019 | 69 | 44 | None | None | $6,078 |
| 2018 | 66 | 42 | 0% (0) | None | $5,918 |
| 2017 | 66 | 34 | None | None | $9,213 |
| 2016 | 65 | 41 | None | None | $7,079 |
| 2015 | 76 | 39 | None | 21% | $8,319 |
| 2014 | 73 | 40 | 0% (0) | 36% | $6,338 |
| 2013 | 88 | 46 | None | 30% | $7,047 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Estradiol | 19 | $669 | $35 |
2022: 1 drug
| Estradiol | 15 | $529 | $35 |
2021: 1 drug
| Estradiol | 20 | $790 | $39 |
2020: 2 drugs
| Estradiol | 13 | $569 | $44 |
| Triamcinolone Acetonide | 13 | $114 | $9 |
2019: 2 drugs
| Estradiol | 19 | $843 | $44 |
| Betamethasone Diprop Augmented | 11 | $512 | $47 |
2018: 1 drug
| Estrace | 26 | $3,194 | $123 |
2015: 2 drugs
| Estrace | 13 | $3,096 | $238 |
| Estradiol | 11 | $315 | $29 |
2014: 2 drugs
| Vagifem | 11 | $3,048 | $277 |
| Estradiol | 12 | $222 | $19 |
2013: 2 drugs
| Premarin | 14 | $2,349 | $168 |
| Nystatin-Triamcinolone | 17 | $1,017 | $60 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ABBVIE INC. · Phase 2 Study of the Efficacy and Safety of Venetoclax in Combination With Ibrutinib in Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma · 2021 | Their institution | $9,350 |
Professional record
- NPI
- 1124191432
- Licence
- CA A86593California A86593: Current · expires 2027-07-31
- Trained
- University of California, Irvine, California College of Medicine, 2002
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A865930
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 1800 Harrison St Fl 7, Oakland, CA, 94612
- NPI first listed
- 2006-11-16
- NPI last updated
- 2022-01-10
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.